FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. PMID 40737559 · Br J Dermatol · 2025-Nov-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up). PMID 40581082 · Br J Dermatol · 2025-Nov-18 The record describes a Phase IIIb/IV randomized trial of upadacitinib for atopic dermatitis, which is a non-oncology condition. The primary efficacy endpoint is a categorical response (EASI 90) and does not involve time-to-event analysis (e.g., OS, PFS, KM curves). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Strategies to improve healthcare team communication structure and quality in resource-variable childhood cancer hospitals (TeamTalk): a study protocol. PMID 41250257 · Implement Sci Commun · 2025-Nov-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Restarting anticoagulation early versus late in patients with chronic subdural hematoma and atrial fibrillation (RELACS): a phase III international multicenter, randomized controlled, two-arm, assessor-blinded trial. PMID 41250110 · Trials · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design. PMID 41249955 · BMC Cancer · 2025-Nov-17 The record is a clinical trial protocol for a randomized study in oncology patients, but it is not a report of formal results from a Phase III or Phase II/III trial. The primary endpoint is venous thromboembolism incidence, which is not a standard oncology efficacy endpoint (e.g., OS, PFS, DFS). No trial results, Kaplan-Meier data, or Hazard Ratios for oncology efficacy are provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology. PMID 41046634 · Eur J Cancer · 2025-Nov-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. PMID 41045691 · Eur J Cancer · 2025-Nov-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial. PMID 40992225 · Eur J Cancer · 2025-Nov-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. PMID 40924496 · J Clin Invest · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients. PMID 40397037 · Am J Hypertens · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A qualitative study of Emotion and Symptom-focused Engagement (EASE): An integrated psychotherapeutic and early palliative care intervention for patients with acute leukemia. PMID 41240159 · Support Care Cancer · 2025-Nov-15 The record describes a qualitative study protocol for a psychotherapeutic intervention within a phase III RCT for acute leukemia. It is not a report of original formal results with a drug-containing intervention and a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhanced recovery after surgery protocol does not reduce the length of postoperative hospitalization after robot-assisted radical prostatectomy. Outcomes from the first randomized controlled trial: the (PROSTA-RAAC) study. PMID 41240114 · World J Urol · 2025-Nov-15 The study is a randomized controlled trial in oncology (prostate cancer), but it evaluates a non-drug intervention (Enhanced Recovery after Surgery protocol) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is length of hospitalization, a continuous outcome, and secondary endpoints include mobilization time and quality of life, not time-to-event measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects and safety of traditional Chinese medicine approaches in cancer symptom care: A systematic review of phase 3 randomized clinical trials. PMID 41217297 · Cancer · 2025-Nov-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. PMID 40673336 · Int J Cancer · 2025-Nov-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma. PMID 40614787 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Preoperative Radiation Therapy for Extremity and Superficial Trunk Soft Tissue Sarcomas: Results of a Prospective, Phase 2 Trial. PMID 40389098 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial. PMID 41239458 · Arthritis Res Ther · 2025-Nov-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study). PMID 41238950 · Support Care Cancer · 2025-Nov-14 The study is an observational investigation of sarcopenia and paclitaxel-induced peripheral neuropathy in early-stage breast cancer. It is not a randomized controlled trial, lacks a definitive Phase III/IIIb or Phase II/III designation, and does not have a primary time-to-event efficacy endpoint as defined (e.g., OS, PFS). The primary outcome is a toxicity incidence, making it a secondary/safety analysis. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial. PMID 41238556 · Sci Rep · 2025-Nov-14 The study meets most inclusion criteria (oncology, human, randomized, drug intervention, time-to-event endpoint with HR, original result) but the trial phase is not explicitly stated in the provided metadata. The criteria require explicit confirmation of Phase III/IIIb or Phase II/III status, which is absent. Therefore, the record is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine. PMID 41092804 · Vaccine · 2025-Nov-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. PMID 41072276 · Vaccine · 2025-Nov-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial. PMID 40932365 · Clin Cancer Res · 2025-Nov-14 The study is a phase II randomized trial with a drug intervention (atezolizumab) and reports primary efficacy results (pCR rates). It is excluded because it is not a phase III/IIIb or phase II/III trial as required, and it does not have a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pathologic complete remission (pCR), a binary outcome, not a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial. PMID 40882625 · Med · 2025-Nov-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Update on Disease-Modifying Pharmacological Treatments for Frontotemporal Dementia (FTD): A Scoping Review of Registered Trials. PMID 41283303 · NeuroSci · 2025-Nov-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme. PMID 41248393 · BMJ Open · 2025-Nov-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A scoping review of thresholds for responder and time-to-event analysis of patient-reported outcomes in breast cancer trials. PMID 41230561 · Br J Clin Pharmacol · 2025-Nov-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. PMID 40888716 · N Engl J Med · 2025-Nov-13 The study is a randomized, Phase IV clinical trial with a primary time-to-event endpoint (composite of death or major adverse cardiovascular events) and a drug intervention (beta-blockers). However, it is excluded because it is not an oncology study, focusing on cardiovascular disease (myocardial infarction) rather than human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis (BIPED study): a statistical analysis plan. PMID 41225556 · Trials · 2025-Nov-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). PMID 41225446 · BMC Cancer · 2025-Nov-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial. PMID 41225165 · J Cancer Surviv · 2025-Nov-12 Study is an original oncology RCT with time-to-event endpoints but does not meet the required drug intervention criterion; phase is also not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma. PMID 41224871 · Sci Rep · 2025-Nov-12 The study is a randomized trial in oncology patients with a drug intervention, but the phase is not specified (no explicit mention of Phase III/IIIb or II/III). The primary endpoint is duration of neutropenia (a hematologic toxicity measure), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis. Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| EXPRESSION OF CONCERN: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial. PMID 41224475 · BMJ · 2025-Nov-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping. PMID 40533147 · Heart · 2025-Nov-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Multidisciplinary Team-Based Refined Nursing on Outcomes in Elderly Patients with Liver Cirrhosis and Upper Gastrointestinal Bleeding. PMID 41325392 · J Vis Exp · 2025-Nov-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Slow Versus Rapid Advancement of Enteral Feeding on Intestinal Oxygenation in Preterm Infants. PMID 41300644 · Children (Basel) · 2025-Nov-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy: a study protocol of double-center, double-blind, randomized controlled trial. PMID 41219803 · Trials · 2025-Nov-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies. PMID 41217554 · Clin Exp Med · 2025-Nov-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bariatric metabolic surgery and cancer risk: Target trial emulation using iterative time distribution matching. PMID 41217501 · Biomol Biomed · 2025-Nov-11 The study is an observational retrospective cohort study using target trial emulation methodology, not a randomized controlled trial. The intervention is bariatric metabolic surgery, which is a surgical procedure, not a drug-containing intervention. The study is not in a Phase III/IIIb or Phase II/III randomized trial framework. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial. PMID 41213939 · Signal Transduct Target Ther · 2025-Nov-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Narrative therapy and resilience training improve recovery and survival after intersphincteric resection for low rectal cancer: a randomized trial. PMID 41191913 · Oncologist · 2025-Nov-11 The trial is a randomized, oncology study with a time-to-event endpoint (DFS/OS) and is the original report. However, the intervention is a psychosocial program (narrative therapy and resilience training), not a drug-containing intervention as required by the cohort definition. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. PMID 41071964 · Neurology · 2025-Nov-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer. PMID 41014160 · Oncologist · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. PMID 40720747 · Blood Adv · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. PMID 41258596 · Discov Oncol · 2025-Nov-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study. PMID 41214650 · BMC Med · 2025-Nov-10 The study is excluded because the intervention is dietary (lycopene intake), not a drug-containing intervention. Additionally, while it is a randomized trial (PREDIMED), this specific analysis is a prospective cohort study within that trial, and the endpoint is cancer incidence as a preventive measure, not a primary/key secondary time-to-event efficacy endpoint for a drug in a definitive oncology trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial. PMID 41212417 · Support Care Cancer · 2025-Nov-10 The study is a randomized controlled trial in oncology with a drug intervention, but it does not include a time-to-event efficacy endpoint (e.g., OS, PFS). It evaluates a non-drug intervention for managing chemotherapy side effects and quality of life, which falls outside the required scope. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol. PMID 41213710 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial. PMID 41213708 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of ciprofol versus propofol on gastrointestinal motility in patients undergoing laparoscopic radical resection for colorectal cancer: study protocol for a randomised controlled trial. PMID 41213705 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Addition of baseline histology and fecal calprotectin does not reduce placebo rates in ulcerative colitis clinical trials: post-hoc analysis of patient-level data. PMID 41208025 · J Crohns Colitis · 2025-Nov-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |